Middle East & Africa Nucleic Acid Therapeutics Contract Manufacturing Market Size & Outlook
Related Markets
MEA nucleic acid therapeutics contract manufacturing market highlights
- The MEA nucleic acid therapeutics contract manufacturing market generated a revenue of USD 451.0 million in 2024.
- The market is expected to grow at a CAGR of 14.3% from 2025 to 2033.
- In terms of segment, rna-based therapies was the largest revenue generating type in 2024.
- Gene Therapy is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2025 to 2033.
MEA data book summary
| Market revenue in 2024 | USD 451.0 million |
| Market revenue in 2033 | USD 1,454.6 million |
| Growth rate | 14.3% (CAGR from 2025 to 2033) |
| Largest segment | Rna-based therapies |
| Fastest growing segment | Gene Therapy |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, RNA-based Therapies |
| Key market players worldwide | Lonza Group Ltd, Thermo Fisher Scientific Inc, Catalent Inc, Wuxi AppTec Co Ltd, AGC Biologics, Agilent Technologies Inc, Ajinomoto Bio-Pharma Services, BioSpring Gesellschaft für Biotechnologie mBH, Bachem Holding AG, CordenPharma, Danaher Corp, Eurofins Scientific SE, Avecia, BioCina, Kaneka Corp |
Other key industry trends
- In terms of revenue, MEA region accounted for 4.6% of the global nucleic acid therapeutics contract manufacturing market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 5,426.5 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Nucleic Acid Therapeutics Contract Manufacturing Market Scope
Nucleic Acid Therapeutics Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Avecia | View profile | 501-1000 | Milford, Massachusetts, United States, North America | http://www.avecia.com |
| BioSpring Gesellschaft für Biotechnologie mBH | View profile | 501-1000 | Frankfurt, Hessen, Germany, Europe | http://www.biospring.de |
| Ajinomoto Bio-Pharma Services | View profile | 1001-5000 | San Diego, California, United States, North America | https://ajibio-pharma.com |
| BioCina | View profile | 101-250 | Thebarton, South Australia, Australia, Oceania | https://www.biocina.com/ |
| CordenPharma | View profile | 5001-10000 | Plankstadt, Baden-Wurttemberg, Germany, Europe | http://cordenpharma.com |
| Bachem Holding AG | View profile | 2006 | Hauptstrasse 144, Bubendorf, Switzerland, 4416 | https://www.bachem.com |
| AGC Biologics | View profile | 1001-5000 | Bothell, Washington, United States, North America | http://www.agcbio.com/ |
| Kaneka Corp | View profile | 13284 | 3-2-4, Nakanoshima, Kita-ku, Osaka, Japan, 530-8288 | http://www.kaneka.co.jp |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| Wuxi AppTec Co Ltd | View profile | 41116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | https://www.wuxiapptec.com |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Agilent Technologies Inc | View profile | 17700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | https://www.agilent.com |
| Danaher Corp | View profile | 63000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | https://www.danaher.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Middle East & Africa nucleic acid therapeutics contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nucleic acid therapeutics contract manufacturing market will help companies and investors design strategic landscapes.
Rna-based therapies was the largest segment with a revenue share of 72% in 2024. Horizon Databook has segmented the Middle East & Africa nucleic acid therapeutics contract manufacturing market based on gene therapy, rna-based therapies covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to Middle East & Africa nucleic acid therapeutics contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa nucleic acid therapeutics contract manufacturing market databook
-
Our clientele includes a mix of nucleic acid therapeutics contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa nucleic acid therapeutics contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa nucleic acid therapeutics contract manufacturing market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
MEA nucleic acid therapeutics contract manufacturing market size, by country, 2021-2033 (US$M)
Middle East & Africa Nucleic Acid Therapeutics Contract Manufacturing Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
